<DOC>
	<DOCNO>NCT00700830</DOCNO>
	<brief_summary>This study conduct Africa . The aim study assess safety efficacy Levemir® treatment insulin naive patient type 2 diabetes normal clinical practice condition Algeria .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Efficacy Levemir® Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Informed consent obtain trialrelated activity Type 2 diabetes HbA1c 79 % Insulin naive Inadequate control oral antidiabetic therapy judge investigator Patients type 1 diabetes Hypersensitivity Levemir® excipients Pregnancy , desire pregnancy within next 6 month HbA1c great equal 9 % Known suspect allergy trial product excipients Subjects unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>